Skip to content
MarketScale
‹ Back to IndustriesSciences

Increasing Diversity in STEM Means Creating More Early Education Opportunities for STEM Exposure

It is no secret that STEM fields have long been lacking in diversity. Even as women have become the majority of holders for undergraduate degrees, they still are underrepresented in STEM. For example, recent research from the National Center for Science and Engineering Statistics shows meager progress on diversity in STEM; the STEM workforce…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · Diversity in StemEducationHigh SchoolsInequity
Share

Key takeaways

01

It is no secret that STEM fields have long been lacking in diversity.

02

Even as women have become the majority of holders for undergraduate degrees, they still are underrepresented in STEM.

03

For example, recent research from the National Center for Science and Engineering Statistics shows meager progress on diversity in STEM; the STEM workforce…

It is no secret that STEM fields have long been lacking in diversity. Even as women have become the majority of holders for undergraduate degrees, they still are underrepresented in STEM. For example, recent research from the National Center for Science and Engineering Statistics shows meager progress on diversity in STEM; the STEM workforce is still largely dominated by white professionals, men, and able-bodied individuals. While there’s been progress over the last decade, it’s slow to bare out in the actual spread of socioeconomic demographics.

The issue of diversity in STEM in part starts long before undergrad in high schools. Public school’s funding can vary dramatically, even between geographically close schools. That level of funding can directly impact student’s access to internships, mentors, and academic experiences especially within the STEM field.

Some professionals in STEM fields and the larger sciences industry are taking solutions into their own hands through the launch of nonprofit localized education centers which aim to bring science, technology, engineering and math education to K-12 students. It’s exactly what Reedy Wade, the Vice President of Academy Engagement and Impact at career readiness nonprofit NAF, is working to implement across the communities she and her team serve.

Reedy’s Thoughts

“While today’s job landscape comes with challenges, inequities, and economic and social disparities that have marginalized far too many students in this country, NAF is committed to bringing schools and businesses together to ensure that students, particularly girls of color, are supported, prepared, and inspired to pursue and achieve careers in STEM.

It truly all begins with exposure to the right academic experiences, the right internship, the right mentor and connections or just having access to the right door at the right time. With greater access and opportunity to participate in work-based learning and connect with mentors who help them build their aspirations, high school students, especially those in under-resourced communities, can move toward a life of upward economic mobility and success.”

Article written by Graham P. Johnson.

About the author

S
Sciences

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512